… respiratory syndrome coronavirus (MERS-CoV), … protease inhibitors. With the recent reporting
of the X-ray crystal structure of the SARS-CoV-2 M pro , studies to discover M pro inhibitors …

… SARS-CoV-2 M pro activity assay, we screened a collection of protease inhibitors, such as
reported M pro inhibitors … human immunodeficiency virus (HIV) protease inhibitors. At 10 μM, …

… This section summarizes the research progress of SARS-CoV-2 M pro inhibitors. … development
based on cysteine protease inhibitors, whose significance is not limited to SARS-CoV-2. …

… inhibitors of SARS-CoV 3CL pro . Attempts have been made to provide a complete description
of the structural features and binding modes of these inhibitors under many conditions. …

… In this work, a set of more than 40 inhibitors targeting the SARS-CoV PL pro was synthesized.
Starting from the previously described inhibitor 2 a, new compounds with antiproteolytic …

… protease inhibitor capable of binding a variety of viral proteases, including SARS-CoV-2 M …
bind and inhibit additional proteases such as the SARS-CoV-2 papain-like protease (PL pro ), …

… of SARS-CoV-2 and SARS-CoV inhibitors, here we collect all available SARS-CoV-2 and
SARS-CoV M pro inhibitors … We highlight highly potent inhibitors, analyze their structures and …

… -like protease (3CL pro ) of Coronavirus. Considering the severity of the spread of coronavirus,
… of finding the new inhibitors against the vital pathway of the corona virus to expedite the …

… 3CL pro inhibition. (10) In the present study, we repositioned and investigated the potential
of our SARS-CoV-1 inhibitors as anti-SARS-CoV-2 drugs. In particular, inhibitors containing …

… crystal structure of SARS-CoV-2 M pro in complex with the protease inhibitor PF-07321332
reveals critical insight for pharmaceutical development. With the emergence of SARS-CoV-2 …